NCT05132088 - Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity | Biotech Hunter

Enrollment

201

Participants

Timeline

Start Date

November 16, 2021

Primary Completion Date

July 11, 2023

Study Completion Date

September 1, 2023

Conditions

Overweight and Obesity

Interventions

DRUG

semaglutide 50 mg

"Participants will have semaglutide for 68 weeks and will have 1 tablet every morning.~Dose gradually increased to 50 mg."

DRUG

placebo (semaglutide)

Participants will have placebo tablets for 68 weeks and will have 1 tablet every morning.

Trial Locations (13)

Seoul National University Bundang Hospital, Gyeonggi-do

Gachon University Gil Medical Center, Incheon

Kyungpook National University Hospital, Daegu

Iryouhoujinsyadan Shoureikan Shinsapporo Seiryou Hospital, Sapporo

Tsuruma Kaneshiro Diabetes Clinic, Yamato-shi

OCROM Clinic, Suita-shi

Naka Kinen Clinic, Ibaraki

Toranomon Hospital, Endocrinology and Metabolism, Minato-ku, Tokyo

Osaka University Hospital, Osaka

Takatsuki Red Cross Hospital, Osaka

Tokyo Center Clinic, Tokyo

ToCROM Clinic, Tokyo

Kangbuk Samsung Hospital, Seoul